Intensity Therapeutics (INTS) provided an update on its patent portfolio including the recent issuance in December 2025 of a new patent in the U.S. entitled “A Method of Treating Cancer”. Patents now granted in 41 countries protect the company’s novel intratumoral technology, including lead compound INT230-6. INT230-6, Intensity’s lead proprietary investigational product candidate, is designed for direct intratumoral injection. INT230-6 was discovered using Intensity’s proprietary DfuseRxSM technology platform.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INTS:
- Intensity Therapeutics Expands ATM Equity Offering Capacity
- Intensity Therapeutics price target adjusted to $30 at Alliance Global
- Intensity Therapeutics provides update on INVINCIBLE-4 Study
- Intensity Therapeutics, Inc. (INTS) Q4 Earnings Cheat Sheet
- Intensity Therapeutics Regains Nasdaq Compliance, Stabilizing Market Listing